Eli Lilly and Company (NYSE:LLY) has seen impressive growth in recent years, largely due to the success of its glucagon-like peptide ... sales of its blockbuster diabetes and obesity drugs.

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

Originally developed for diabetes management, these medications have found a second life as potent weight loss aids. They work by mimicking the action of a hormone called glucagon-like peptide 1 ...

which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 2023, underscoring its robust financial standing. The company’s 2025 revenue guidance ranges ...

If you want to know who really controls Eli Lilly and Company (NYSE:LLY), then you'll have to look at the makeup of its share registry. With 87% stake, institutions possess the maximum shares in ...

This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 2023, ...

If you want to know who really controls Eli Lilly and Company (NYSE:LLY), then you'll have to look at the makeup of its share registry. With 87% stake, institutions possess the maximum shares in the ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.